Brain metabolic changes in patients with disseminated malignant melanoma under immunotherapy
Por:
Sizova, M, Camacho, V, Sampedro, F, Sabate-Llobera, A, Abouzian, S, Stefaneli, P, Duch, J, Fernandez-Leon, A, Lopez-Mora, DA, Estorch, M, Carrio, I, Flotats, A
Publicada:
1 oct 2022
Resumen:
Although there is evidence that chemotherapy can have side effects on metabolism and brain function, there are few studies on the occurrence of these side effects with immunotherapy. The present study was conducted to assess whether brain metabolic changes occur in patients with malignant melanoma under immunotherapy. Thirty-nine patients after surgical intervention and with a diagnosis of malignant melanoma were retrospectively included and were divided into two groups: one group under the first-line therapy with anti-programmed cell death-1 +/- anti-cytotoxic T lymphocyte antigen-4 monoclonal antibodies and the other group without any treatment after surgery, which served as a control. Basal and follow-up whole body and brain 2-[F-18]fluoro-2-deoxy-D-glucose (F-18]FDG) PET/computed tomography (CT) studies were performed. Changes in brain glucose metabolism after treatment initiation of the immunotherapy group were compared with the findings in the control group. In addition, longitudinal regression analysis to investigate whether the time under immunotherapy influenced the changes of brain metabolism was performed. None of the patients presented cognitive impairment or other neurological alterations between basal and follow-up brain [F-18]FDG PET/CT examinations. The statistical analysis revealed a significant relative SUV (SUVr)-loss in the left frontal region in patients of the immunotherapy group compared with the control group, with r(adjusted) = -0.62 and P = 0.008. Severity of SUVr-loss was correlated with duration of treatment. Patients with disseminated malignant melanoma receiving immunotherapy may present a decrease of brain metabolism in the left frontal region, which is related with time-under-treatment, without any clinical evidence of neurological disorder.
Filiaciones:
Sizova, M:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Barcelona, Spain
Camacho, V:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Barcelona, Spain
Sampedro, F:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Barcelona, Spain
Hosp Santa Creu & Sant Pau, Inst Recerca, Barcelona, Spain
Sabate-Llobera, A:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Barcelona, Spain
Abouzian, S:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Barcelona, Spain
Stefaneli, P:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Barcelona, Spain
Duch, J:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Barcelona, Spain
Fernandez-Leon, A:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Barcelona, Spain
Lopez-Mora, DA:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Barcelona, Spain
Estorch, M:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Barcelona, Spain
Carrio, I:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Barcelona, Spain
Flotats, A:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Barcelona, Spain
|